Domains of Daily Physical Activity in Children with Mitochondrial Disease: A 3D Accelerometry Approach by Koene, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/181895
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
RESEARCH REPORT
Domains of Daily Physical Activity in Children with
Mitochondrial Disease: A 3D Accelerometry Approach
Saskia Koene • Ilse Dirks • Esmee van Mierlo •
Pascal R. de Vries • Anjo J.W.M. Janssen •
Jan A.M. Smeitink • Arjen Bergsma • Hans Essers •
Kenneth Meijer • Imelda J.M. de Groot
Received: 16 June 2016 /Revised: 7 November 2016 /Accepted: 5 December 2016 /Published online: 17 January 2017
# SSIEM and Springer-Verlag Berlin Heidelberg 2017
Abstract Feasible, sensitive and clinically relevant out-
come measures are of extreme importance when designing
clinical trials. For paediatric mitochondrial disease, no
robust end point has been described to date. The aim of
this study was to select the domains of daily physical
activity, which can be measured by 3D accelerometry, that
could serve as sensitive end points in future clinical trials in
children with mitochondrial disorders.
In this exploratory observational study, 17 patients with
mitochondrial disease and 16 age- and sex-matched
controls wore 3D accelerometers at the upper leg, upper
arm, lower arm and chest during one weekend. Using the
raw data obtained by the accelerometers, we calculated the
following outcome measures: (1) average amount of
counts per hour the sensors were worn; (2) the maximal
intensity; (3) the largest area under the curve during
30 min and (4) categorized activities lying, standing or
being dynamically active. Measuring physical activity
during the whole weekend was practically feasible in all
participants. We found good face validity by visually
correlating the validation videos and activity diaries to the
accelerometer data-graphs. Patients with mitochondrial
disorders had significantly lower peak intensity and were
resting more, compared to their age- and sex-matched
peers.
Finally, we suggest domains of physical activity that
could be included when measuring daily physical activity in
children with mitochondrial disorders, preferably using
more user-friendly devices. These include peak activity
parameters for the arms (all patients) and legs (ambulatory
patients). We recommend using or developing devices that
measure these domains of physical activity in future clinical
studies.
Introduction
Since lack of energy and fatigue are among the most
burdensome complaints experienced by children with
mitochondrial disease and their parents (Koene et al.
2013b), this symptom should be covered in future clinical
trials. However, testing fatigue or fatigability in this
paediatric population is challenging, since many children
are not able to rate their fatigue using one of the widely
used self-report fatigue questionnaires (Swanink et al.
1995; Gordijn et al. 2011) because of intellectual dis-
abilities and most endurance tests (e.g. cycle ergometry
(LeMura et al. 2001) are not feasible or too burdensome
for children with mitochondrial disorders. Besides,
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measuring performance in a laboratory situation may not
always reflect the disabilities experienced in daily life
since the performance in daily life may differ from the
abilities of the child (Abel et al. 2003; Beenakker et al.
2005; Parreira et al. 2010).
In a recent review of all published studies in mitochon-
drial disease, an international expert panel recommended
(amongst others) to use validated and clinically meaningful
end points (Pfeffer et al. 2013). Only very few studies
investigating outcome measures in paediatric mitochondrial
disease have been published and most of the outcome
measures studied are not generally applicable among
children with mitochondrial disease. In a small group of
children with non-proven mitochondrial disease, Martens
et al. (2014) found lower physical activity level compared
to healthy peers.
We hypothesized that measuring daily physical activ-
ity at home is a clinically relevant outcome measure and
a good reflection of the fatigue experienced by children
with mitochondrial disease in daily life. Physical activity
is defined as “any bodily movement produced by
skeletal muscle contraction that results in caloric
expenditure” and includes sports, hobbies, playing,
walking, cycling and activities of daily living (Caspersen
et al. 1985). Physical activity has many domains,
including the type, intensity, frequency and duration of
the physical activity. It is currently not known which of
these aspects is most affected in patients with mitochon-
drial disorders.
Daily physical activity in a home situation can be
measured by using 3D accelerometry (Bjornson 2005;
McDonald et al. 2005; Capio et al. 2010; Clanchy et al.
2011a, b; Jeannet et al. 2011; Koene et al. 2013a). Many
commercially available activity monitors that are based on
accelerometry measure only general domains of movement,
such as the total amount of body activity, step count and
position. Such monitors provide only the calculated
parameters, and not the raw acceleration data. In this study,
we aimed to select more detailed domains of physical
activity that can be measured by accelerometry in future
clinical trials. For this study, we selected an accelerometer
(MOX) that provides raw accelerations in 3D, so we could
design a tailored analysis.
Methods
This is an exploratory, observational study, aiming to select
the domains of physical activity that should be measured by
accelerometry in future clinical trials in patients with
mitochondrial disease. The domains of physical activity
were selected based on deviation from healthy age- and
sex-matched peers. Before selecting these domains, the
feasibility and face validity of the 3D accelerometer in this
population was studied.
Accelerometer
For this study, we used a MOX accelerometer (MOX
sensor, model MMOXX1.01, Maastricht Instruments BV,
The Netherlands), that measures accelerations (Range 6G)
in three degrees of freedom with a sample frequency of
25 Hz. The acceleration data was filtered with a Butter-
worth 0.025–7.5 Hz 4th-order high-pass filter to remove
noise and movement artefacts. This accelerometer provides
raw data which can be used for tailored analyses.
A set of four or five sensors was used. The acceler-
ometers were attached to the chest, dominant lower arm and
upper arm and to the leg using an attachment band (limbs)
or a top (chest; Fig. 1). If the patient used a wheelchair, a
fifth accelerometer was attached to the wheelchair. The
wheelchair sensor was used to indicate passive moments of
the child.
Fig. 1 The accelerometer localizations. (a) The MOX-accelerometer
is approximately 4.5  4.0  1.4 cm in size and weighs 27 g; (b)
Attachment of the accelerometer to chest; (c) to the lower (dominant)
arm; (d) the upper arm and (e) the (dominant) upper leg
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To estimate the amount of daily activity, various
parameters were calculated from the acceleration data of
each sensor, by using Matlab procedures that were developed
and validated beforehand (Meijer et al. 2014). The first
parameter is the activity counts, which was calculated by
integrating the acceleration over 1-minute episodes and
summing this outcome over all three axes. A constant
acceleration of 1G (gravitational constant) over 1 min
corresponds with 1,000 counts (Meijer et al. 2014). We used
the following outcome measures: (1) average amount of
counts per hour the sensors were worn (average counts (total
amount of counts measured with the sensor/worn h; counts/
h), also referred to activity level); (2) the maximal intensity
(maximal amount of counts per min (counts/min)) and (3)
the largest area under the curve (AUC) during 30 min
(largest AUC during 1/2 h (counts)). The second outcome
measure is an activity classification which categorizes the
performed activities per second into lying, standing or being
dynamically active. Lying and standing are classified
depending on the gravitational angle acting on the poste-
rior-anterior and cranial-caudal axes. Being dynamically
active is classified when the integration of the acceleration
over 1-second episodes is above a pre-defined threshold.
Study Protocol
Study Protocol for Patients
Patients were recruited at the Radboud Centre for Mito-
chondrial Medicine. Patients aged 4–18 years old with a
confirmed mitochondrial disease, either based on patholog-
ical mutations in mtDNA or nuclear DNA or on mitochon-
drial dysfunction in fresh muscle as measured by routine
biochemistry as applied in our centre (Rodenburg 2011),
were eligible for inclusion. This group includes the full
clinical spectrum of mitochondrial disorders, ranging from
patients with exercise intolerance only to wheelchair bound
patients with severe movement disorders. Exclusion cri-
teria: (1) expected by the treating physician that travelling
to the hospital would be too burdensome to the patient; (2)
fever; (3) epilepsia continua; or (4) altered state of
consciousness compared to normal at the time of inclusion.
The number of children was determined by the number of
children that could be included in the same season.
Patients were assessed at the outpatient clinic of the
Radboud Center for Mitochondrial Medicine (RCMM) on
Fridays. An experienced paediatric physiotherapist performed
the Gross Motor Function Measure-88 (GMFM). After the
two tests, parents were instructed how to attach the
accelerometers. Wearing the sensors, patients were – if
possible – instructed to follow a validation protocol (stand-
ardized activities, including waving, throwing a ball, lying
down, sitting, standing, walking and running). In case of
limited physical abilities, the position (orientation) of the arm,
leg and chest was changed passively, if possible at low,
middle and high velocity (intensity). The patient was video-
taped with a synchronized camera during all tests, to be able
to correlate specific movements (e.g. raising an arm, walking,
movement disorders or epilepsy) to the data obtained by the
accelerometer. By correlating these video images with the
accelerometer data-graphs (correspondence of orientation and
intensity for each sensor) we determined the face validity of
the measurements in a laboratory situation.
After completion of the validation protocol, patients
were asked to wear the sensors over the weekend, while the
parents completed an activity diary. Parents were asked to
complete the diary with the exact timing and a description
of the activity (e.g. 12:36–13:18: Lunch, independently
eating bread with knife and fork). For practical reasons
(complexity of data analysis and logistics), we chose to
only measure for 2 days, instead of the recommended
7 days (Cain et al. 2013). Patients were asked to wear the
accelerometers at all waking hours, with the exception of
bathing, showering and swimming. The reported activities
were also correlated to the accelerometer data-graphs
(correspondence of the intensity of the movements during
the described activities) to determine face validity of the
measurements at home.
On Monday, the parents were interviewed by phone for
the feasibility and comfort of the accelerometers with a self-
made questionnaire. Moreover, the parents were interviewed
with the Pediatric Evaluation of Disability Inventory (PEDI),
measuring the performance and capability in the activities of
daily life (Custers et al. 2002; Vos-Vromans et al. 2005). The
PEDI and the GMFM were used to determine the correlation
between activity parameters and gross motor function
(capability) and functional abilities (performance).
Study Protocol for Healthy Controls
The healthy controls were recruited at two regular schools
in the surroundings of Nijmegen. Healthy controls were
eligible for inclusion when they were healthy and aged
between 4 and 18 years. Exclusion criteria: (1) confirmed
diagnosis of Attention Deficit and Hyperactivity Disorder
(ADHD); (2) symptoms of exercise intolerance, fatigue or
muscle problems or (3) the child was under regular
surveillance of a paediatrician. Controls were sex- and
age-matched to a single patient.
Healthy controls were instructed in their home-environ-
ment in the same weekend as the age- and sex-matched
patient. The attachment and localization of the accelerom-
eters was the same as the patient protocol. Validation, using
the validation protocol and videotaping, was also similar to
the patient protocol. Healthy controls were also instructed
to wear the accelerometer during waking hours and to keep
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an activity diary. On Monday, the feasibility and comfort of
the accelerometers was evaluated.
Analyses
Feasibility
Feasibility was tested using the parent reported complica-
tions of wearing the accelerometers and the quantity of the
data obtained (% of subjects; the time the device collected
data as a percentage of the intended measurement period
(Saturday 0:00 to Sunday 23:59) and the time the device
collected data as a percentage of the time the sensor was
worn). Only patients in whom more than one sensor failed
were excluded from the analyses. For the patients in which
one sensor failed, only the available data are presented.
Face Validity
Face validity was assessed by visually correlating the videos
with the obtained accelerometer data-graphs (correspondence
of orientation and intensity for each sensor) during the
validation protocol in each subject. Subsequently, the data
from the diarieswas correlated to the accelerometer data-graphs
(correspondence of the intensity of the movements during the
described activities). Only when the video images and
described activities clearly did not correlate to the data-graphs,
the data were excluded from the analyses.We assessed whether
the percentage of dynamic activity and the total leg activity was
lower in non-ambulatory children compared to ambulatory
children. Finally, the functional abilities, assessed by the
GMFM and the PEDI were correlated to the measurements.
Patients Versus Controls
We compared patients and their age- and sex-matched
controls on each of the above-mentioned variables.
Subgroup Analyses
Based on the molecular finding in each patients, we’ve
created three subgroups: (1) genetically confirmed primary
mitochondrial disease; (2) genetically confirmed secondary
mitochondrial disease (patients with a mutation in a non-
mitochondrial gene with biochemically proven mitochon-
drial dysfunction, either with or without a proven link to
mitochondrial processes) and (3) biochemically confirmed
mitochondrial dysfunction.
Statistical Analyses
Because of the relatively small number of subjects included
in our study, we used non-parametric tests to assess
differences and correlations. We used a p-value of 0.05
for statistical significance; because of the exploratory
character of this study, we did not use adjust critical p-
values using the Bonferroni method. Missing data were not
replaced. All analyses were performed using IBM’s SPSS
statistics software packages, version 20.0.0.1. Correlation
coefficients were interpreted in accordance with the guide-
lines provided at the BMJ website (http://www.bmj.com/
about-bmj/resources-readers/publications/statistics-square-
one/11-correlation-and-regression).
Ethics
This study was approved by the regional Medical Research
Ethics Committee (MREC NL50560.091.14). In accor-
dance with the Helsinki agreement, written informed
consent was obtained from participant’s legal guardian
and, where indicated, the participant.
Results
Study Population
Seventeen patients and 16 healthy age- and sex-matched
controls were included in this study from February to May
2015. One healthy control withdrew his consent 1 day
before the measurement would start and no other age- and
sex-matched control was available for that weekend. The
groups were comparable with respect to age, sex, BMI and
sports- and highest education of parents, but – as expected
– differed significantly with respect to height, weight, time
spent at sports and the level of education of the child
(Supplementary Table 1). There was a wide variability in
the genetic, biochemical, clinical and functional abilities in
the children with mitochondrial disease (Supplementary
Table 2).
Feasibility
All participants, including patients with severe mental
retardation, tolerated wearing the accelerometers for the
duration of the measurement. The full study protocol was
completed by 29 children (88% of total study population): 3
participants temporarily removed the sensors: 2 removed
the top to ventilate after exercise and because of a party, 1
did not attach the chest-sensor on Sunday because of
discomfort of the top and 1 boy lost his upper leg sensor
during outdoor playing. Five sensors failed to record any
data and the batteries of one sensor failed during the
measurements (18% of all participants; 4% of all measure-
ments). Due to these technical issues, 6% of the total
measured time and 8% of the time the sensors were worn
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was missing in 6 participants (4 patients and 2 healthy
controls). One healthy control had to be excluded from the
analyses because he lost his upper leg sensor and his upper
arm sensor failed to record any data. Most subjects wore
their sensors from the moment they awoke to the moment
they undressed for bed; three participants removed all
sensors after dinner (averagely sensors were worn 94% of
the woken time). The time the sensors were taken off
because of swimming, showering or bathing was 1.9%. The
time the sensors were not worn because of lack of
understanding or lack of motivation was 8.7%.
Face Validity
For all patients and healthy controls, the movements
(orientation, intensity) at the videos corresponded to the
acceleration data that was visualized in graphs (Fig. 2).
Dynamic activity (i.e. walking) and the activity of arms
and legs was higher in ambulatory compared to non-
ambulatory patients. For these analyses, we excluded a
boy who was not able to walk but had excellent abilities
to move (on his buttock), but not to walk, from these
analyses since we could not define in which group he
belonged. We found a (very) strong and significant
correlation between the motor abilities as measured with
the GMFM and the resting percentage (r ¼ 0.82), the
largest amount of activity of the leg during half an hour
(r ¼ 0.65) and the peak-activity of the lower arm
(r ¼ 0.67; all p < 0.0001). The score on the mobility
domain of the PEDI (functional abilities) also correlated
very strongly with the resting percentage (r ¼ 0.87)
and strongly with the largest amount of activity of the leg
during half an hour (r ¼ 0.70) and the peak-activity
of the leg (r ¼ 0.60; all p < 0.0001; Supplementary
Table 3).
Patients Versus Controls
We observed no difference in any of the activity variables
between all children (including both healthy controls and
patients) aged 12 years and older and children under
12 years of age (p ¼ 0.005–0.815). We also observed no
difference in any of the activity variables between patients
under or above 12 years of age (p ¼ 0.05–0.79). The same
accounts for the difference between boys and girls
(p ¼ 0.05–1.00 and p ¼ 0.005–1.00, respectively).
Almost all activity variables were significantly lower in
patients with mitochondrial disorders compared to their
age- and sex-matched controls (Table 1). We saw no
difference in the quantity of arm activity between patients
and controls. When comparing individual results, all but
one patient had higher percentages of rest during the
weekend, except for one girl matched to a healthy girl
who had to study for her final exams during the whole
weekend (couple 2 in Supplementary Fig. 1).
Subgroup Analyses
When comparing patients with genetically confirmed
primary mitochondrial disease to their peers, we found a
similar pattern of differences compared to all patients
versus their matched controls. Only the maximal intensity
of the upper- and lower arm and the largest AUC during
half an hour for the upper arm reached significance in this
small group. Patients with genetically confirmed secondary
mitochondrial dysfunction differed significantly in their %
of rest and standing, as well as their maximal intensity for
the upper leg and lower arm. For patients with biochemi-
cally confirmed mitochondrial dysfunction, only the wear
time differed significantly from their healthy peers,
although the median peak activities were all (not signifi-
cantly) lower. When comparing the latter two groups to the
genetically confirmed primary mitochondrial disease
patients, patients with genetically confirmed secondary
mitochondrial disease (which are all non-ambulatory) are
resting more and have a lower AUC during half an hour for
the upper leg. Patients with biochemically confirmed
mitochondrial dysfunction did not differ significantly from
the patients genetically confirmed primary mitochondrial
disease.
Not surprisingly, the leg activity of non-ambulatory
patients was lower compared to ambulatory patients
(Table 2). In fact, the activity of ambulatory patients did
not deviate from healthy peers (p ¼ 0.05–0.9), with the
exception of the largest AUC in 30 min for the upper leg.
The other peak intensity parameters did not reach signifi-
cance, but showed substantially lower values compared to
their peers. Non-ambulatory patients deviated from healthy
controls – as expected – in all leg parameters and position
parameters, but also in peak activity. The maximal intensity
parameters for the arm were decreased to the largest extent
and most significantly.
Patients with myopathy and encephalopathy were com-
parable with respect to all activity parameters
(p ¼ 0.3–0.9).
Recommendations
Based on the difference (both significance and the
magnitude of the difference) between patients and healthy
subjects, we made recommendations on which variables to
use in future accelerometry studies in children with
mitochondrial disease (Table 3). We recommend the use
of maximal intensity and largest AUC in 30 min variables.
JIMD Reports 11
Fig. 2 Raw data. (a) Raw data representing the orientation and
activity of the sensors during the validation protocol (patient 17). (b,
c) Raw data representing the physical activity of two representative
patients during the validation protocol in the laboratory. (c, d) Raw
data representing the physical activity of one day for a matched
couple. The couple (couple 3) with the most striking difference was
selected, the healthy control is in panel (c) and panel (d) represents the
patient
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For non-ambulatory patients, arm activity variables should
be used instead of leg variables.
Discussion
In this exploratory study, we aimed to select the domains of
daily physical activity, measured by 3D accelerometry, that
could be sensitive end points in future clinical trials. Although
we experienced technical difficulties with the hardware in
18% of the subjects (4% of the measurements), we showed
that measuring physical activity in a home-situation with 3D
accelerometers was feasible and had good face validity in all
seventeen childrenwithmitochondrial disease. By comparing
the children to an age- and sex-matched healthy peer whowas
measured within the same weekend, we selected domains of
movement that deviated from normal in children with
mitochondrial disorders (Table 3).
The percentages of rest, standing and dynamic activity
were significantly different between patients and their
healthy peers. However, since we observed no differences
in these percentages between matched controls and non-
ambulatory patients (who are sitting in a wheelchair), we
don’t recommend the use domains of physical activity for
future studies. Arm activity levels (amount of activity) were
comparable between patients and healthy controls. Our data
could not confirm that this was due to compensatory use of
arms in non-ambulatory children or due to high levels of
unpurposeful arm activity in children with movement
disorders such as ataxia. We advice not to include arm
activity level as a domain of physical activity in children
with mitochondrial disorders. The peak activity and largest
area under the curve for both arms and legs showed the
largest magnitude of difference and was significantly
different between patients and controls for most parameters,
also when only the nine patients with genetically confirmed
primary mitochondrial disease were included. For ambula-
tory patients, the largest magnitude of change is observed in
the peak activity of the upper leg, although a significant
difference was observed only for the largest AUC in half an
hour for leg activity. Both variables have a large spread
across both healthy controls and patients. For non-ambula-
tory patients, the peak activity and the largest AUC of the
arms were decreased to the same extent, but this decrease
was most significant for the peak activity. All peak intensity
parameters correlated moderately to gross motor function.
For this study, we selected the MOX-accelerometer, a
device with opportunities to design a tailored data-analysis.
It is known that measuring for longer periods decreased
variability substantially in patients with cerebral palsy (CP)
(Mitchell et al. 2015). However, we deliberately chose to
measure physical activity only during the days in which the
child was performing physical activity to their own desire
and was not challenged with mental exercise (i.e. the
weekend versus school week), since the aim of this study was
to select domains of physical activity that deviated from the
normal population and not to reliably quantify the amount of
daily movement. We used 4–5 accelerometers instead of one,
to be able to quantify movement patterns of the upper- and
lower arm, the chest and the upper leg. This allowed us to
draw conclusions about the orientation and the intensity of
movements of these body parts, but is obviously less
desirable from a patient perspective (Kirby et al. 2012).
Previously,Martens et al. (2014) showed that children with
mitochondrial disease have a lower activity level compared
to healthy controls and less time spent in moderate to
vigorous activities, using a commercially available physical
activity device. The resting percentage in the study by
Martens et al. was lower compared to what we found, even
in ambulatory patients only. This could be due to selection
bias: Martens et al. studied ambulatory children without
severe cognitive impairment and none of them had a
genetically confirmed mitochondrial disease. Adults with
mitochondrial disease also show lower habitual physical
activity compared to matched controls (Apabhai et al. 2011).
Interestingly, also the number of breaks in sedentary activity
was reduced and longer periods of rest were observed. The
resting percentage found in our study was comparable to the
resting percentage in ambulatory normally weighted children
with Down’s-, William’s- and Prader-Willi syndrome (Nord-
strom et al. 2013) and patients with CP, when both patient
groups were stratified based on their walking abilities (Gorter
et al. 2012). Five young ambulatory boys (4–6 years) with
Duchenne Muscular Dystrophy (DMD) (Jeannet et al. 2011),
who were significantly younger than our study subjects,
spent much less time resting, but had comparable levels of
dynamic activity when compared to our ambulatory patients.
In contrast to most previous studies, we also included non-
ambulatory patients in our study. Measuring daily activity in
Table 3 Recommendations for future accelerometry studies in
children with mitochondrial disease
Ambulatory
patients
Non-
ambulatory
patients
The percentage of the day spent
resting or in dynamic activity
NR NR
The level of activity of legs NR NR
The level of activity of arms NR NR
Maximal intensity of legs H NR
Maximal intensity of arms R R
Largest AUC in 30 min of legs H NR
Largest AUC in 30 min of arms R R
AUC area under the curve, H highly recommended, NR not
recommended, R recommended
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these patients is challenging, because accelerations elicited
by the wheelchair are also measured by the other sensors. We
found that the wheelchair accounted for about one fourth of
the leg activity level in non-ambulatory children.
This study was performed on a relatively small and
clinically heterogeneous group of patients but indicates
abnormal domains of physical activity in patients with both
high and limited abilities. Patients are compared to age- and
sex-matched controls, who were measured in the same
weekend to correct for weather conditions. Weaknesses
include the substantial level of technical failures and the
relatively short measurement time, which were caused by
the use of the studied accelerometers and are not likely to
play a major role in commercially available accelerometers.
Other methodological issues inherent to measuring activity
with accelerometers include: the lack of measurement of
stable, sustained body positions and that the current data
analysis is not able to differentiate between meaningful
movements and aberrant movements, such as myoclonus or
ataxia. Another weakness is that we included a heteroge-
neous population and that not all patients have a confirmed
genetic mitochondrial disease: out of 17 patients, only 9
patients have a genetically confirmed “primary” mitochon-
drial disease. During analysis of this subgroup, we
confirmed that also if only these patients were analysed,
peak activity parameters had the highest magnitude and
significance of difference. The activity parameters did not
differ between patients with genetically confirmed primary
mitochondrial disease and patients with biochemically
confirmed mitochondrial dysfunction. Patients with geneti-
cally confirmed secondary mitochondrial disease did differ
on three parameters, but these findings need to be
interpreted carefully since all patients with genetically
confirmed secondary mitochondrial disease were non-
ambulatory. Since most patients were not able to reliably
complete questionnaires regarding their level of fatigue,
these were not included in this study.
This study provides insight into the domains of physical
activity that are abnormal in children with mitochondrial
disease. Since this approach is data-driven only, we are
currently performing a more patient-centred approach in
which the clinically relevant domains of movement are
explored in close dialogue with patients and their families.
Combining the results of both studies, we aim to select a
simple, commercially available activity monitor, that
provides insight in the clinically relevant aspects of daily
physical activity of children with mitochondrial disease.
This accelerometer should be validated in a larger and more
homogeneous study population, with longer measurement
period and standardization of family activities during the
measurements, to provide representative activity patterns
and reduce random variability. Validation should include at
least the following aspects: acceptability, feasibility, test-
retest reliability, including the influence of weather con-
ditions and seasons, validity, especially in wheelchair
bound patients, and responsivity.
In conclusion, accelerometry is a promising method to
quantify the highly burdensome fatigue in children with
mitochondrial disease in daily practice as well as natural
history studies. The method is safe, feasible and well
tolerated. Whether accelerometry is reliable and sensitive
enough to detect changes during clinical trials needs to be
studied in more detail.
Take Home Message
Children with mitochondrial disorders have lower peak
activity rather than a lower amount activity compared to
healthy peers.
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